Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 240 entries
Sorted by: Best Match Show Resources per page
Multiple Endocrine Neoplasia Type 1: Latest Insights.

Endocrine reviews

Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV.
PMID: 33249439
Endocr Rev. 2021 Mar 15;42(2):133-170. doi: 10.1210/endrev/bnaa031.

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an autosomal dominant pattern, is continuing to raise great interest for endocrinology, gastroenterology, surgery, radiology, genetics, and molecular biology specialists. There have been 2 major...

Cite
Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133-170doi: 10.1210/endrev/bnaa031.
Brandi, M. L., Agarwal, S. K., Perrier, N. D., Lines, K. E., Valk, G. D., & Thakker, R. V. (2021). Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocrine reviews, 42(2), 133-170. https://doi.org/10.1210/endrev/bnaa031
Brandi, Maria Luisa, et al. "Multiple Endocrine Neoplasia Type 1: Latest Insights." Endocrine reviews vol. 42,2 (2021): 133-170. doi: https://doi.org/10.1210/endrev/bnaa031
Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021 Mar 15;42(2):133-170. doi: 10.1210/endrev/bnaa031. PMID: 33249439; PMCID: PMC7958143.
Copy Download .nbib Format: NLM
Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study.

Ophthalmology

Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, Flowers BE, Grover DS, Strouthidis NG, Panarelli JF.
PMID: 34051211
Ophthalmology. 2021 Dec;128(12):1710-1721. doi: 10.1016/j.ophtha.2021.05.023. Epub 2021 May 27.

PURPOSE: To compare the effectiveness and safety of the MicroShunt versus trabeculectomy in patients with primary open-angle glaucoma (POAG).DESIGN: One-year results from a 2-year, prospective, randomized, multicenter, noninferiority study (NCT01881425) conducted in the United States and Europe.PARTICIPANTS: Eligible patients...

Cite
Baker ND, Barnebey HS, Moster MR, et al. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology. 2021;128(12):1710-1721doi: 10.1016/j.ophtha.2021.05.023.
Baker, N. D., Barnebey, H. S., Moster, M. R., Stiles, M. C., Vold, S. D., Khatana, A. K., Flowers, B. E., Grover, D. S., Strouthidis, N. G., Panarelli, J. F. (2021). Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology, 128(12), 1710-1721. https://doi.org/10.1016/j.ophtha.2021.05.023
Baker, N Douglas, et al. "Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study." Ophthalmology vol. 128,12 (2021): 1710-1721. doi: https://doi.org/10.1016/j.ophtha.2021.05.023
Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, Flowers BE, Grover DS, Strouthidis NG, Panarelli JF. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology. 2021 Dec;128(12):1710-1721. doi: 10.1016/j.ophtha.2021.05.023. Epub 2021 May 27. PMID: 34051211.
Copy Download .nbib Format: NLM
Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.

Clinical cancer research : an official journal of the American Association for Cancer Research

Hackeng WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, Valk GD, Vriens MR, Offerhaus GJA, Geisenberger C, Brosens LAA.
PMID: 33355250
Clin Cancer Res. 2021 Mar 01;27(5):1341-1350. doi: 10.1158/1078-0432.CCR-20-3281. Epub 2020 Dec 22.

PURPOSE: The primary origin of neuroendocrine tumor metastases can be difficult to determine by histopathology alone, but is critical for therapeutic decision making. DNA methylation-based profiling is now routinely used in the diagnostic workup of brain tumors. This has...

Cite
Hackeng WM, Dreijerink KMA, de Leng WWJ, et al. Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool. Clin Cancer Res. 2020;27(5):1341-1350doi: 10.1158/1078-0432.CCR-20-3281.
Hackeng, W. M., Dreijerink, K. M. A., de Leng, W. W. J., Morsink, F. H. M., Valk, G. D., Vriens, M. R., Offerhaus, G. J. A., Geisenberger, C., & Brosens, L. A. A. (2021). Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1341-1350. https://doi.org/10.1158/1078-0432.CCR-20-3281
Hackeng, Wenzel M, et al. "Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1341-1350. doi: https://doi.org/10.1158/1078-0432.CCR-20-3281
Hackeng WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, Valk GD, Vriens MR, Offerhaus GJA, Geisenberger C, Brosens LAA. Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool. Clin Cancer Res. 2021 Mar 01;27(5):1341-1350. doi: 10.1158/1078-0432.CCR-20-3281. Epub 2020 Dec 22. PMID: 33355250.
Copy Download .nbib Format: NLM
[No title available]

EJNMMI research

de Vries LH, Lodewijk L, Braat AJAT, Krijger GC, Valk GD, Lam MGEH, Borel Rinkes IHM, Vriens MR, de Keizer B.
PMID: 32144510
EJNMMI Res. 2020 Mar 06;10(1):18. doi: 10.1186/s13550-020-0610-x.

No abstract available.

Cite
de Vries LH, Lodewijk L, Braat AJAT, et al. . EJNMMI Res. 2020;10(1):18doi: 10.1186/s13550-020-0610-x.
de Vries, L. H., Lodewijk, L., Braat, A. J. A. T., Krijger, G. C., Valk, G. D., Lam, M. G. E. H., Borel Rinkes, I. H. M., Vriens, M. R., & de Keizer, B. (2020). . EJNMMI research, 10(1), 18. https://doi.org/10.1186/s13550-020-0610-x
de Vries, Lisa H, et al. "." EJNMMI research vol. 10,1 (2020): 18. doi: https://doi.org/10.1186/s13550-020-0610-x
de Vries LH, Lodewijk L, Braat AJAT, Krijger GC, Valk GD, Lam MGEH, Borel Rinkes IHM, Vriens MR, de Keizer B. . EJNMMI Res. 2020 Mar 06;10(1):18. doi: 10.1186/s13550-020-0610-x. PMID: 32144510; PMCID: PMC7060303.
Copy Download .nbib Format: NLM
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.

Pharmaceuticals (Basel, Switzerland)

Chamberlain S, Cole HD, Roque J, Bellnier D, McFarland SA, Shafirstein G.
PMID: 32605213
Pharmaceuticals (Basel). 2020 Jun 28;13(7). doi: 10.3390/ph13070137.

Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based...

Cite
Chamberlain S, Cole HD, Roque J, et al. TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel). 2020;13(7)doi: 10.3390/ph13070137.
Chamberlain, S., Cole, H. D., Roque, J., Bellnier, D., McFarland, S. A., & Shafirstein, G. (2020). TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel, Switzerland), 13(7), . https://doi.org/10.3390/ph13070137
Chamberlain, Sarah, et al. "TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro." Pharmaceuticals (Basel, Switzerland) vol. 13,7 (2020). doi: https://doi.org/10.3390/ph13070137
Chamberlain S, Cole HD, Roque J, Bellnier D, McFarland SA, Shafirstein G. TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals (Basel). 2020 Jun 28;13(7). doi: 10.3390/ph13070137. PMID: 32605213; PMCID: PMC7407920.
Copy Download .nbib Format: NLM
Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series.

European heart journal. Case reports

Tschöpe C, Van Linthout S, Spillmann F, Posch MG, Reinke P, Volk HD, Elsanhoury A, Kühl U.
PMID: 31365055
Eur Heart J Case Rep. 2019 Sep 01;3(3). doi: 10.1093/ehjcr/ytz131.

BACKGROUND : The aetiology of dilated cardiomyopathy (DCM) is highly heterogeneous including genetic and/or acquired (infective, toxic, immune, endocrine, and nutritional) factors. The major part of acquired DCM in developed countries is caused by either viral or autoimmune myocarditis....

Cite
Tschöpe C, Van Linthout S, Spillmann F, et al. Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. Eur Heart J Case Rep. 2019;3(3)doi: 10.1093/ehjcr/ytz131.
Tschöpe, C., Van Linthout, S., Spillmann, F., Posch, M. G., Reinke, P., Volk, H. D., Elsanhoury, A., & Kühl, U. (2019). Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. European heart journal. Case reports, 3(3), . https://doi.org/10.1093/ehjcr/ytz131
Tschöpe, Carsten, et al. "Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series." European heart journal. Case reports vol. 3,3 (2019). doi: https://doi.org/10.1093/ehjcr/ytz131
Tschöpe C, Van Linthout S, Spillmann F, Posch MG, Reinke P, Volk HD, Elsanhoury A, Kühl U. Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series. Eur Heart J Case Rep. 2019 Sep 01;3(3). doi: 10.1093/ehjcr/ytz131. PMID: 31365055; PMCID: PMC6764574.
Copy Download .nbib Format: NLM
Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.

Frontiers in endocrinology

van den Broek MFM, van Nesselrooij BPM, Verrijn Stuart AA, van Leeuwaarde RS, Valk GD.
PMID: 31920960
Front Endocrinol (Lausanne). 2019 Dec 10;10:837. doi: 10.3389/fendo.2019.00837. eCollection 2019.

Pituitary adenomas (PA) are amongst the most prevalent intracranial tumors, causing complications by hormonal overproduction or deficiency and tumor mass effects, with 95% of cases occurring sporadically. Associated germline mutations (

Cite
van den Broek MFM, van Nesselrooij BPM, Verrijn Stuart AA, et al. Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review. Front Endocrinol (Lausanne). 2019;10:837doi: 10.3389/fendo.2019.00837.
van den Broek, M. F. M., van Nesselrooij, B. P. M., Verrijn Stuart, A. A., van Leeuwaarde, R. S., & Valk, G. D. (2019). Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review. Frontiers in endocrinology, 10837. https://doi.org/10.3389/fendo.2019.00837
van den Broek, Medard F M, et al. "Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review." Frontiers in endocrinology vol. 10 (2019): 837. doi: https://doi.org/10.3389/fendo.2019.00837
van den Broek MFM, van Nesselrooij BPM, Verrijn Stuart AA, van Leeuwaarde RS, Valk GD. Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review. Front Endocrinol (Lausanne). 2019 Dec 10;10:837. doi: 10.3389/fendo.2019.00837. eCollection 2019. PMID: 31920960; PMCID: PMC6914701.
Copy Download .nbib Format: NLM
Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma.

Chemical science

Lifshits LM, Roque Iii JA, Konda P, Monro S, Cole HD, von Dohlen D, Kim S, Deep G, Thummel RP, Cameron CG, Gujar S, McFarland SA.
PMID: 33976756
Chem Sci. 2020 Sep 09;11(43):11740-11762. doi: 10.1039/d0sc03875j. eCollection 2020 Nov 21.

Mounting evidence over the past 20 years suggests that photodynamic therapy (PDT), an anticancer modality known mostly as a local treatment, has the capacity to invoke a systemic antitumor immune response, leading to protection against tumor recurrence. For aggressive...

Cite
Lifshits LM, Roque Iii JA, Konda P, et al. Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chem Sci. 2020;11(43):11740-11762doi: 10.1039/d0sc03875j.
Lifshits, L. M., Roque Iii, J. A., Konda, P., Monro, S., Cole, H. D., von Dohlen, D., Kim, S., Deep, G., Thummel, R. P., Cameron, C. G., Gujar, S., & McFarland, S. A. (2020). Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chemical science, 11(43), 11740-11762. https://doi.org/10.1039/d0sc03875j
Lifshits, Liubov M, et al. "Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma." Chemical science vol. 11,43 (2020): 11740-11762. doi: https://doi.org/10.1039/d0sc03875j
Lifshits LM, Roque Iii JA, Konda P, Monro S, Cole HD, von Dohlen D, Kim S, Deep G, Thummel RP, Cameron CG, Gujar S, McFarland SA. Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma. Chem Sci. 2020 Sep 09;11(43):11740-11762. doi: 10.1039/d0sc03875j. eCollection 2020 Nov 21. PMID: 33976756; PMCID: PMC8108386.
Copy Download .nbib Format: NLM
Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.

The American journal of surgical pathology

Hackeng WM, van Beek DJ, Kok ASM, van Emst M, Morsink FHM, van Treijen MJC, Borel Rinkes IHM, Dreijerink KMA, Offerhaus GJA, Valk GD, Vriens MR, Brosens LAA.
PMID: 34560682
Am J Surg Pathol. 2021 Sep 23; doi: 10.1097/PAS.0000000000001811. Epub 2021 Sep 23.

Patients with multiple endocrine neoplasia 1 syndrome (MEN1) often develop multifocal duodenopancreatic neuroendocrine tumors (dpNETs). Nonfunctional pancreatic neuroendocrine tumors (PanNETs) and duodenal gastrinomas are the most frequent origins of metastasis. Current guidelines recommend surgery based on tumor functionality, size...

Cite
Hackeng WM, van Beek DJ, Kok ASM, et al. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. Am J Surg Pathol. 2021;doi: 10.1097/PAS.0000000000001811.
Hackeng, W. M., van Beek, D. J., Kok, A. S. M., van Emst, M., Morsink, F. H. M., van Treijen, M. J. C., Borel Rinkes, I. H. M., Dreijerink, K. M. A., Offerhaus, G. J. A., Valk, G. D., Vriens, M. R., & Brosens, L. A. A. (2021). Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. The American journal of surgical pathology, . https://doi.org/10.1097/PAS.0000000000001811
Hackeng, Wenzel M, et al. "Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1." The American journal of surgical pathology vol. (2021). doi: https://doi.org/10.1097/PAS.0000000000001811
Hackeng WM, van Beek DJ, Kok ASM, van Emst M, Morsink FHM, van Treijen MJC, Borel Rinkes IHM, Dreijerink KMA, Offerhaus GJA, Valk GD, Vriens MR, Brosens LAA. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. Am J Surg Pathol. 2021 Sep 23; doi: 10.1097/PAS.0000000000001811. Epub 2021 Sep 23. PMID: 34560682.
Copy Download .nbib Format: NLM
It Takes Three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug.

ChemPhotoChem

Chettri A, Roque JA, Schneider KRA, Cole HD, Cameron CG, McFarland SA, Dietzek B.
PMID: 34337147
ChemPhotoChem. 2021 May;5(5):421-425. doi: 10.1002/cptc.202000283. Epub 2021 Jan 19.

TLD1433 is the first Ru(II) complex to be tested as a photodynamic therapy agent in a clinical trial. In this contribution we study TLD1433 in the context of structurally-related Ru(II)-imidozo[4,5-f][1,10]phenanthroline (ip) complexes appended with thiophene rings to decipher the...

Cite
Chettri A, Roque JA, Schneider KRA, et al. It Takes Three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug. ChemPhotoChem. 2021;5(5):421-425doi: 10.1002/cptc.202000283.
Chettri, A., Roque, J. A., Schneider, K. R. A., Cole, H. D., Cameron, C. G., McFarland, S. A., & Dietzek, B. (2021). It Takes Three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug. ChemPhotoChem, 5(5), 421-425. https://doi.org/10.1002/cptc.202000283
Chettri, Avinash, et al. "It Takes Three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug." ChemPhotoChem vol. 5,5 (2021): 421-425. doi: https://doi.org/10.1002/cptc.202000283
Chettri A, Roque JA, Schneider KRA, Cole HD, Cameron CG, McFarland SA, Dietzek B. It Takes Three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug. ChemPhotoChem. 2021 May;5(5):421-425. doi: 10.1002/cptc.202000283. Epub 2021 Jan 19. PMID: 34337147; PMCID: PMC8323708.
Copy Download .nbib Format: NLM
Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.

The American journal of surgical pathology

Hackeng WM, van Beek DJ, Kok ASM, van Emst M, Morsink FHM, van Treijen MJC, Borel Rinkes IHM, Dreijerink KMA, Offerhaus GJA, Valk GD, Vriens MR, Brosens LAA.
PMID: 34560682
Am J Surg Pathol. 2022 Feb 01;46(2):159-168. doi: 10.1097/PAS.0000000000001811.

Patients with multiple endocrine neoplasia 1 syndrome (MEN1) often develop multifocal duodenopancreatic neuroendocrine tumors (dpNETs). Nonfunctional pancreatic neuroendocrine tumors (PanNETs) and duodenal gastrinomas are the most frequent origins of metastasis. Current guidelines recommend surgery based on tumor functionality, size...

Cite
Hackeng WM, van Beek DJ, Kok ASM, et al. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. Am J Surg Pathol. 2022;46(2):159-168doi: 10.1097/PAS.0000000000001811.
Hackeng, W. M., van Beek, D. J., Kok, A. S. M., van Emst, M., Morsink, F. H. M., van Treijen, M. J. C., Borel Rinkes, I. H. M., Dreijerink, K. M. A., Offerhaus, G. J. A., Valk, G. D., Vriens, M. R., & Brosens, L. A. A. (2022). Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. The American journal of surgical pathology, 46(2), 159-168. https://doi.org/10.1097/PAS.0000000000001811
Hackeng, Wenzel M, et al. "Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1." The American journal of surgical pathology vol. 46,2 (2022): 159-168. doi: https://doi.org/10.1097/PAS.0000000000001811
Hackeng WM, van Beek DJ, Kok ASM, van Emst M, Morsink FHM, van Treijen MJC, Borel Rinkes IHM, Dreijerink KMA, Offerhaus GJA, Valk GD, Vriens MR, Brosens LAA. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1. Am J Surg Pathol. 2022 Feb 01;46(2):159-168. doi: 10.1097/PAS.0000000000001811. PMID: 34560682.
Copy Download .nbib Format: NLM
Clinico-genetic findings in 509 frontotemporal dementia patients.

Molecular psychiatry

Wagner M, Lorenz G, Volk AE, Brunet T, Edbauer D, Berutti R, Zhao C, Anderl-Straub S, Bertram L, Danek A, Deschauer M, Dill V, Fassbender K, Fliessbach K, Götze KS, Jahn H, Kornhuber J, Landwehrmeyer B, Lauer M, Obrig H, Prudlo J, Schneider A, Schroeter ML, Uttner I, Vukovich R, Wiltfang J, Winkler AS, Zhou Q, Ludolph AC, Oexle K, Otto M, Diehl-Schmid J, Winkelmann J.
PMID: 34561610
Mol Psychiatry. 2021 Oct;26(10):5824-5832. doi: 10.1038/s41380-021-01271-2. Epub 2021 Sep 24.

Frontotemporal dementia (FTD) is a clinically and genetically heterogeneous disorder. To which extent genetic aberrations dictate clinical presentation remains elusive. We investigated the spectrum of genetic causes and assessed the genotype-driven differences in biomarker profiles, disease severity and clinical...

Cite
Wagner M, Lorenz G, Volk AE, et al. Clinico-genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry. 2021;26(10):5824-5832doi: 10.1038/s41380-021-01271-2.
Wagner, M., Lorenz, G., Volk, A. E., Brunet, T., Edbauer, D., Berutti, R., Zhao, C., Anderl-Straub, S., Bertram, L., Danek, A., Deschauer, M., Dill, V., Fassbender, K., Fliessbach, K., Götze, K. S., Jahn, H., Kornhuber, J., Landwehrmeyer, B., Lauer, M., Obrig, H., Prudlo, J., Schneider, A., Schroeter, M. L., Uttner, I., Vukovich, R., Wiltfang, J., Winkler, A. S., Zhou, Q., Ludolph, A. C., Oexle, K., Otto, M., Diehl-Schmid, J., & Winkelmann, J. (2021). Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular psychiatry, 26(10), 5824-5832. https://doi.org/10.1038/s41380-021-01271-2
Wagner, Matias, et al. "Clinico-genetic findings in 509 frontotemporal dementia patients." Molecular psychiatry vol. 26,10 (2021): 5824-5832. doi: https://doi.org/10.1038/s41380-021-01271-2
Wagner M, Lorenz G, Volk AE, Brunet T, Edbauer D, Berutti R, Zhao C, Anderl-Straub S, Bertram L, Danek A, Deschauer M, Dill V, Fassbender K, Fliessbach K, Götze KS, Jahn H, Kornhuber J, Landwehrmeyer B, Lauer M, Obrig H, Prudlo J, Schneider A, Schroeter ML, Uttner I, Vukovich R, Wiltfang J, Winkler AS, Zhou Q, Ludolph AC, Oexle K, Otto M, Diehl-Schmid J, Winkelmann J. Clinico-genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry. 2021 Oct;26(10):5824-5832. doi: 10.1038/s41380-021-01271-2. Epub 2021 Sep 24. PMID: 34561610.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 240 entries